TY - JOUR T1 - Nuclear Medicine and Wall Street: An Evolving Relationship JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 20S LP - 24S DO - 10.2967/jnumed.118.220798 VL - 60 IS - Supplement 2 AU - Mike Sherman AU - Rachel Levine Y1 - 2019/09/01 UR - http://jnm.snmjournals.org/content/60/Supplement_2/20S.abstract N2 - Until recently, it has been challenging to engage Wall Street and large pharmaceutical companies in radiopharmaceutical opportunities. The modest economic prospects of most diagnostic radiopharmaceuticals have not attracted keen interest from the broader business community, despite the rapid advancement of diagnostic imaging capabilities and their increasingly crucial role in the therapeutic process. Similarly, compelling science supporting select radiopharmaceutical therapies in oncology has been overshadowed by the unique challenges posed by this class of drugs and historical commercial failures that serve as sobering reminders of risk. Fortunately, a few notable successes in the targeted radioligand therapeutic space are changing this dynamic, fueling a new flow of investor capital into these technologies and inciting increased merger and acquisition activity that has yielded significant value creation for investors. If the nuclear medicine industry is able to continue to effectively manage historical challenges, then there is significant opportunity for a new and promising wave of radioligand therapies to significantly change the oncology treatment paradigm and elevate the profile of the entire nuclear medicine sector. ER -